Lilly's tirzepatide impresses with diabetes results

17 February 2021

US drugmaker Eli Lilly (NYSE: LLY) has announced trial results on tirzepatide, a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist molecule that represents a new class of medicines being studied for the treatment of type 2 diabetes.

Tirzepatide led to significant HbA1C and body weight reductions from baseline in adults with type 2 diabetes in the SURPASS-3 and SURPASS-5 Phase III trials after 52 weeks and 40 weeks, respectively.

"HbA1C levels and weight are high priorities throughout the type 2 diabetes treatment journey"In top-line results, the primary and all key secondary endpoints were met for both efficacy and treatment-regimen estimands in SURPASS-3, which compared tirzepatide to titrated insulin degludec, and in SURPASS-5, which compared tirzepatide to placebo, both as an add-on to titrated insulin glargine.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK